

Table 1 Previous case reports of osimertinib-induced ILD in patients with NSCLC harboring EGFR T790M

Case	Age	Sex	EGFR status	Smoking pack-year	Onset of ILD	Chest CT pattern	Treatment for ILD	Outcome	Re-challenge (mg/body)	Corticosteroid during re-challenge	Recurrence of ILD	Effect of osimertinib (Initial/ Re-challenge)
1 (ref6)	32	M	Exon 19 deletion, T790M	NA	4.5 months	GGO	Dexa 10 mg/day	Improved	No *	Dexa 10 mg/day	No	PR/NA
2 (ref7)	38	F	L858R, T790M	Never	31 days	Diffuse GGO	Cessation	Improved	Osimertinib (80 mg)	No	Yes	PR/PR
3 (ref8)	75	F	Exon 19 deletion, T790M	Never	64 days	ILST	PSL 0.5 mg/kg	Improved	Osimertinib (40 mg)	PSL 0.5 mg/kg →tapered 5 mg/day	No	PR/PR
4 (ref9)	77	F	L858R, T790M	Never	14 days	Diffuse GGO	Cessation	Improved	No	NA	No	PR/NA
5 (ref10)	82	M	Exon 19 deletion, T790M	Never	8 months	Diffuse GGO	Steroid	Improved	Osimertinib (80 mg)	PSL 40 mg/day →tapered off	No	PR/PR
6 (ref10)	60	M	Exon 19 deletion, T790M	NA	6 weeks	Diffuse GGO	Steroid	Improved	Osimertinib (NA)	PSL 20 mg/day →tapered off	Yes	NA/PR
7 (ref11)	75	M	L858R, T790M	Never	34 days	Diffuse GGO Peribronchial consolidation	mPSL 500 mg/day	Improved	No	NA	No	NA/NA
8 (ref12)	59	F	Exon 19 deletion, T790M	NA	63 days	Patchy GGO and consolidation	Steroid pulse	Improved	No	NA	No	PR/NA
9 (ref13)	62	M	Exon 19 deletion, T790M	30	82 days	Multiple GGO	PSL 0.5 mg/kg	Improved	Osimertinib (40 mg)	PSL 25 mg/day	No	NA/SD
10	75	F	Exon 19 deletion, T790M	Never	6 months	OP pattern	PSL 0.6 mg/kg	Improved	Osimertinib (80 mg)	PSL 20 mg/day →tapered 5mg/day	No	PR/SD

ILD, interstitial lung disease, CT; computed tomography, GGO; ground-glass opacity, ILST; interlobular septal thickening. This patient also suffered pleural effusion  
 DEXA; dexamethasone PSL; prednisolone, mPSL; methylprednisolone, NA; not available  
 \*Osimertinib was continued with a dose reduction.  
 PR; partial response, SD; stable disease

**Table 2 CT pattern of first-generation EGFR-TKI-induced ILD**

Reference	EGFR-TKI	CT pattern					Total
		GGO pattern <sup>a</sup>	OP-like pattern <sup>b</sup>	AEP-like pattern <sup>c</sup>	AIP-like pattern <sup>d</sup>	Others	
(14)	gefitinib	24 (47.1%)	7 (13.7%)	1 (2.0%)	12 (23.5%)	7 (13.7%)	51
(15)	gefitinib	8 (34.8%)	3 (13.0%)	5 (21.7%)	7 (30.4%)	0	23
(16)	erlotinib	NA	NA	NA	63 (22.3%)	NA	283

EGFR-TKI = epidermal growth factor receptor tyrosine kinase inhibitor; GGO = ground-glass opacity, OP = organizing pneumonia; AEP = acute eosinophilic pneumonia; AIP = acute interstitial pneumonia; NA = not available; ILD = interstitial lung disease; CT = computed tomography

<sup>a</sup>GGO pattern: Only nonspecific area with ground-glass opacity

<sup>b</sup>OP-like pattern: Multifocal areas of airspace consolidation

<sup>c</sup>AEP-like pattern: Patchy distribution of areas with ground-glass opacity accompanied by interlobular septal thickening

<sup>d</sup>AIP-like pattern: Extensive bilateral ground-glass opacity or airspace consolidations with traction bronchiectasis